Candel (CADL) Reports Upbeat Data From Lung Cancer Study

Image Source: Zacks Investment Research Apart from NSCLC, CAN-2409 is also being developed for several cancer indications, including pancreatic ductal adenocarcinoma (PDAC) and prostate cancer. Last month, CADL announced positive interim data from the phase II study evaluating CAN-2409 plus valacyclovir, together with SoC chemoradiation, followed by resection for borderline resectable PDAC. The updated interim data from the ongoing phase II study showed that experimental treatment with CAN-2409 led to notab ...